The first experience of using a new variant of combined antihypertensive therapy – a combination of amlodipine and azilsartan medoxomil in the form of a set of tablets (co-pack) in a calendar blister. сlinical cases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Arterial hypertension is a multifactorial disease, the progression of which is caused by several pathogenetic links, including activation of the renin-angiotensin-aldosterone system, endothelial dysfunction, and structural changes in the vascular wall of the arteries with increasing stiffness. Against the background of high blood pressure, target organs (heart, blood vessels, brain, kidneys, and retina) are affected, and as a result, associated clinical conditions develop, including atherosclerotic vascular damage, vascular changes in brain matter with the development of cognitive deficits, coronary heart disease, and various types of cardiac arrhythmias. The main objective of hypertension treatment is to prescribe therapy to achieve the target blood pressure level and protect the target organs. Also, in addition to prescribing effective antihypertensive medications, an important aspect of patient treatment is a personalized approach, taking into account concomitant pathology and the specific daily blood pressure profile of each patient to maximize possible reduction of cardiovascular risk and improve prognosis. This publication provides examples of personalization of antihypertensive therapy based on the use of the new drug Edarbi AM, which is a set of tablets in a calendar blister and includes, in addition to the blocker of the renin-angiotensin-aldosterone system azilsartan medoxomil, a scored tablet of amlodipine, which allows individualizing strategies for lowering blood pressure depending on each specific clinical situation.

Full Text

Restricted Access

About the authors

O. D. Ostroumova

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; Central State Medical Academy of the Administrative Department of the President of the Russian Federation; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Author for correspondence.
Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0002-0795-8225
SPIN-code: 3910-6585

Professor, MD

 

Russian Federation, Moscow; Moscow; Saint Petersburg

A. I. Kochetkov

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0001-5801-3742
SPIN-code: 9212-6010

Associate Professor, Candidate of Medical Sciences

Russian Federation, Moscow

T. M. Ostroumova

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0003-1499-247X
SPIN-code: 5043-4713

Candidate of Medical Sciences

Russian Federation, Moscow; Saint Petersburg

N. A. Shatalova

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0001-6823-6077
SPIN-code: 2456-6361

Candidate of Medical Sciences

Russian Federation, Moscow

T. V. Filippova

Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

Email: ostroumova.olga@mail.ru
ORCID iD: 0009-0004-7241-0938
Russian Federation, Moscow

N. M. Doldo

Central Clinical Hospital «RZD-Medicine»

Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0002-0821-7373
Russian Federation, Moscow

References

  1. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЭ. Кардиоваскулярная терапия и профилактика. 2014; 13 (4): 4–14 [Boytsov S.A., Balanova Yu.A., Shalnova S.A. et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ESSE study. Cardiovascular therapy and prevention. 2014; 13 (4): 4–14 (in Russ.)]. doi: 10.15829/1728-8800-2014-4-4-14
  2. Баланова Ю.А., Драпкина О.М., Куценко В.А. и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023; 22 (8S): 3785 [Balanova Yu.A., Drapkina O.M., Kutsenko V.A. et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular therapy and prevention. 2023; 22 (8S): 3785 (in Russ.)]. doi: 10.15829/1728-8800-2023-3785
  3. Rubattu S., Pagliaro B., Pierelli G. et al. Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. Int J Mol Sci. 2014; 16 (1): 823–39. doi: 10.3390/ijms16010823
  4. Piqueras L., Sanz M.J. Angiotensin II and leukocyte trafficking: New insights for an old vascular mediator. Role of redox-signaling pathways. Free Radic Biol Med. 2020; 157: 38–54. doi: 10.1016/j.freeradbiomed.2020.02.002
  5. Schmieder R.E. End organ damage in hypertension. Dtsch Arztebl Int. 2010; 107 (49): 866–73. doi: 10.3238/arztebl.2010.0866
  6. Kućmierz J., Frąk W., Młynarska E. et al. Molecular Interactions of Arterial Hypertension in Its Target Organs. Int J Mol Sci. 2021; 22 (18): 9669. doi: 10.3390/ijms22189669
  7. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360 (9349): 1903–13. doi: 10.1016/s0140-6736(02)11911-8
  8. Piskorz D. Hypertensive Mediated Organ Damage and Hypertension Management. How to Assess Beneficial Effects of Antihypertensive Treatments? High Blood Press Cardiovasc Prev. 2020; 27 (1): 9–17. doi: 10.1007/s40292-020-00361-6
  9. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015; 29 (1): 1–6. doi: 10.1038/jhh.2014.36
  10. Cohuet G., Struijker-Boudier H. Mechanisms of target organ damage caused by hypertension: therapeutic potential. Pharmacol Ther. 2006; 111 (1): 81–98. doi: 10.1016/j.pharmthera.2005.09.002
  11. Артериальная гипертензия у взрослых. Клинические рекомендации, утвержденные Минздравом России. М., 2024 [Arterial hypertension in adults. Clinical recommendations approved by the Ministry of Health of Russia. М., 2024 (in Russ.)]. URL: https://cr.minzdrav.gov.ru/
  12. Чернявский М.А., Иртюга О.Б., Янишевский С.Н. и др. Российский консенсус по диагностике и лечению пациентов со стенозом сонных артерий. Российский кардиологический журнал. 2022; 27 (11): 5284 [Chernyavsky M.A., Irtyuga O.B., Yanishevsky S.N. et al. Russian consensus statement on the diagnosis and treatment of patients with carotid stenosis. Russian Journal of Cardiology. 2022; 27 (11): 5284 (in Russ.)]. doi: 10.15829/1560-4071-2022-5284
  13. Probstfield J.L., O'Brien K.D. Progression of cardiovascular damage: the role of renin-angiotensin system blockade. Am J Cardiol. 2010; 105 (1 Suppl): 10A-20A. doi: 10.1016/j.amjcard.2009.10.006
  14. Леонова М.В. Клиническая фармакология и клиническая эффективность амлодипина. Данные доказательной медицины. Медицинский Совет. 2014; 12: 25–32 [Leonova M. Clinical pharmacology and clinical efficacy of amlodipine. Evidence-based data. Medical Council. 2014; 12: 25–32 (in Russ.)]. doi: 10.21518/2079-701X-2014-12-25-32
  15. Verdecchia P., Gentile G., Angeli F. et al. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis. 2012; 6 (2): 81–91. doi: 10.1177/1753944712444866
  16. Bulsara K.G., Patel P., Cassagnol M. Amlodipine. 2024 Apr 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2025. URL: https://www.ncbi.nlm.nih.gov/books/NBK519508
  17. Nissen S.E., Tuzcu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004; 292 (18): 2217–25. doi: 10.1001/jama.292.18.2217
  18. Brener S.J., Ivanc T.B., Poliszczuk R. et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J. 2006; 152 (6): 1059–63. doi: 10.1016/j.ahj.2006.07.022
  19. Pitt B., Byington R.P., Furberg C.D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000; 102 (13): 1503–10. doi: 10.1161/01.cir.102.13.1503
  20. Гиляревский С.Р., Карпов Ю.А., Лучникова Е.А. и др. Сравнение эффективности и переносимости комбинации азилсартана и амлодипина с монотерапией амлодипином и комбинациями амлодипина с другими блокаторами рецепторов ангиотензина II. Кардиологический вестник. 2024; 19 (4-2): 161–71 [Gilyarevsky S.R., Karpov Yu.A., Luchnikova E.A. et al. Efficacy and tolerability of azilsartan combined with amlodipine and amlodipine monotherapy and combinations of amlodipine with other angiotensin II receptor blockers. Russian Cardiology Bulletin. 2024; 19 (4-2): 161–71 (in Russ.)]. doi: 10.17116/Cardiobulletin202419042161
  21. Азилсартана медоксомил. Инструкция по медицинскому применению. Государственный реестр лекарственных средств [Электронный ресурс] [Azilsartan medoxomil. Instructions for medical use. State Register of Medicines [Electronic resource] (in Russ.)]. URL: https://grls.rosminzdrav.ru/
  22. Sica D., White W.B., Weber M.A. et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011; 13 (7): 467–72. doi: 10.1111/j.1751-7176.2011.00482.x
  23. de Gasparo M., Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. 1995; 59 (3): 303–11. doi: 10.1016/0167-0115(95)00085-p
  24. Miura S., Okabe A., Matsuo Y. et al. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res. 2013; 36 (2): 134–9. doi: 10.1038/hr.2012.147
  25. Li W., Wang C., Zhang D. et al. Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2. Aging (Albany NY). 2021; 13 (9): 12996–3005. doi: 10.18632/aging.202973
  26. Расин М.С. γ-Рецепторы, активируемые пролифераторами пероксисом, и артериальная гипертония (уроки истории исследований). Терапевтический архив. 2013; 85 (9): 118–23 [Rasin M.S. Peroxisome proliferator-activated receptors-γ and hypertension: Lessons of the history of researches. Therapeutic Archive. 2013; 85 (9): 118–23 (in Russ.)].
  27. Карева Е.Н.. Эволюция сартанов или все ли сартаны одинаковы? Клиническая фармакология и терапия. 2016; 25 (3): 11–21 [Kareva E.N. Evolution of angiotensin receptor blockers. Clin Pharmacol Ther. 2016; 25 (3): 11–21 (in Russ.)].
  28. Белик Е.В., Груздева О.В., Дылева Ю.А. и др. Особенности продукции ингибитора активатора плазминогена-1 локальными жировыми депо различной локализации при сердечно-сосудистых заболеваниях. Российский кардиологический журнал. 2022; 27 (4): 4866 [Belik E.V., Gruzdeva O.V., Dyleva Yu.A. et al. Features of plasminogen activator inhibitor-1 synthesis by local fat depots of different localization in cardiovascular diseases. Russian Journal of Cardiology. 2022; 27 (4): 4866 (in Russ.)]. doi: 10.15829/1560-4071-2022- 4866.
  29. Амлодипин. Инструкция по медицинскому применению. Государственный реестр лекарственных средств [Электронный ресурс] [Amlodipine. Instructions for medical use. State Register of Medicines [Electronic resource] (in Russ.)]. URL: https://grls.rosminzdrav.ru/
  30. Адашева Т.В., Задионченко В.С., Багатырова К.М. и др. Антагонисты рецепторов к ангиотензину II – эволюция представлений. Consilium Medicum. 2011; 13 (5): 47–51 [Adasheva T.V., Zadionchenko V.S., Bagatyrova K.M., et al. Antagonisty retseptorov k angiotenzinu II – evolyutsiya predstavleniy. Consilium Medicum. 2011; 13 (5): 47–51 (in Rus.)].
  31. Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26 (7): 4594 [Arakelyan M.G., Bockeria L.A., Vasilieva E.Yu. et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021; 26 (7): 4594 (in Russ.)]. doi: 10.15829/1560-4071-2021-4594
  32. Madrid A.H., Bueno M.G., Rebollo J.M. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002; 106 (3): 331–6. doi: 10.1161/01.CIR.0000022665.18619.83
  33. Soliman E.Z., Rahman A.F., Zhang Z.M. et al. Effect of Intensive Blood Pressure Lowering on the Risk of Atrial Fibrillation. Hypertension. 2020; 75 (6): 1491–6. doi: 10.1161/HYPERTENSIONAHA.120.14766
  34. White W.B., Weber M.A., Sica D. et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011; 57 (3): 413–20. doi: 10.1161/HYPERTENSIONAHA.110.163402
  35. Folstein M.F., Folstein S.E., McHugh P.R. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189–98. doi: 10.1016/0022-3956(75)90026-6
  36. Nasreddine Z.S., Phillips N.A., Bédirian V. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53 (4): 695–9. doi: 10.1111/jgs.15925
  37. Kuber B., Fadnavis M., Chatterjee B. Role of angiotensin receptor blockers in the context of Alzheimer's disease. Fundam Clin Pharmacol. 2023; 37 (3): 429–45. doi: 10.1111/fcp.12872
  38. Зуева И.Б. Артериальная гипертония и когнитивные нарушения: возможные механизмы развития, диагностика, подходы к терапии. Терапевтический архив. 2015; 87 (12): 96–100 [Zueva I.B. Hypertension and cognitive impairments: Possible mechanisms of development, diagnosis, and approaches to therapy. Therapeutic Archive. 2015; 87 (12): 96–100 (in Russ.)]. doi: 10.17116/terarkh2015871296-100
  39. Wong Zhang D.E., Sobey C.G., De Silva T.M. The role of angiotensin peptides in the brain during health and disease. In Angiotensin; Pilowsky P.M., Ed.; Academic Press: Cambridge, MA, USA, 2023; pp. 749–73.
  40. Patel S., Rauf A., Khan H. et al. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomed Pharmacother. 2017; 94: 317–25. doi: 10.1016/j.biopha.2017.07.091
  41. Ahmed H.A., Ishrat T. The Brain AT2R-a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics. Mol Neurobiol. 2020; 57 (8): 3458–84. doi: 10.1007/s12035-020-01964-9
  42. Royea J., Hamel E. Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets. Geroscience. 2020; 42 (5): 1237–56. doi: 10.1007/s11357-020-00231-y
  43. Lee H.W., Kim S., Jo Y. et al. Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: A nationwide population-based cohort study. Front Aging Neurosci. 2023; 15: 1137197. doi: 10.3389/fnagi.2023.1137197
  44. Canavan M., O'Donnell M.J. Hypertension and Cognitive Impairment: A Review of Mechanisms and Key Concepts. Front Neurol. 2022; 13: 821135. doi: 10.3389/fneur.2022.821135
  45. Toth P., Tucsek Z., Sosnowska D. et al. Age-related autoregulatory dysfunction and cerebromicrovascular injury in mice with angiotensin II-induced hypertension. J Cereb Blood Flow Metab. 2013; 33 (11): 1732–42. doi: 10.1038/jcbfm.2013.143
  46. Bowman G.L., Dayon L., Kirkland R. et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimers Dement. 2018; 14 (12): 1640–50. doi: 10.1016/j.jalz.2018.06.2857
  47. Rodrigue K.M., Rieck J.R., Kennedy K.M. et al. Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. JAMA Neurol. 2013; 70 (5): 600–6. doi: 10.1001/jamaneurol.2013.1342
  48. Парфенов В.А., Старчина Ю.А. Когнитивные нарушения у пациентов с артериальной гипертензией и их лечение. Неврология, нейропсихиатрия, психосоматика. 2011; 3 (1): 27–33 [Parfenov V.A., Starchinab Y.A. Cognitive disorders in patients with essential hypertension and their treatment. Neurology, Neuropsychiatry, Psychosomatics. 2011; 3 (1): 27–33 (in Russ.)]. doi: 10.14412/2074-2711-2011-130
  49. Киндарова А.А., Абдышова С.А., Фанталис Д. и др. Некоторые аспекты терапии сосудистых когнитивных расстройств. Эффективная фармакотерапия. 2020; 16 (23): 14–20 [Kindarova A.A., Abdyshova S.A., Fantalis D. et al. Some aspects of vascular cognitive disorders therapy. Effective pharmacotherapy. 2020; 16 (23): 14–20 (in Russ.)]. doi: 10.33978/2307-3586-2020-16-23-14-20
  50. Fournier A., Achard J.M., Boutitie F. et al. Is the angiotensin II Type 2 receptor cerebroprotective? Curr Hypertens Rep. 2004; 6 (3): 182–9. doi: 10.1007/s11906-004-0067-8
  51. Ababei D.-C., Bild V., Macadan I. et al. Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia. Pharmaceutics. 2023; 15 (9): 2290. doi: 10.3390/pharmaceutics15092290
  52. Feldman L., Vinker S., Efrati S. et al. Amlodipine treatment of hypertension associates with a decreased dementia risk. Clin Exp Hypertens. 2016; 38 (6): 545–9. doi: 10.3109/10641963.2016.1174249
  53. Kerkhofs D., Helgers R., Hermes D. et al. Amlodipine limits microglia activation and cognitive dysfunction in aged hypertensive mice. J Hypertens. 2023; 41 (7): 1159–67. doi: 10.1097/HJH.0000000000003445
  54. Воронина Т.А., Иванова Е.А. Комбинированное применение мексидола с известными лекарственными средствами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019; 119 (4): 115–24 [Voronina T.A., Ivanova E.A. Combined administration of mexidol with known medicines. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119 (4): 115–24 (in. Russ.)]. doi: 10.17116/jnevro2019119041115

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Electrocardiogram of patient L., 61 years old

Download (320KB)
Indexing metadata
3. Fig. 3. Results of 24-hours blood pressure monitoring of patient L., 61 years old, before correction of therapy

Download (89KB)
Indexing metadata
4. Fig. 4. Сontrol 24-hours blood pressure monitoring of patient L., 61 years old, during treatment with a combination of azilsartan medoxomil 40 mg and amlodipine 5 mg (Edarbi AM)

Download (125KB)
Indexing metadata
5. Fig. 5. Electrocardiogram of patient M., 55 years old

Download (247KB)
Indexing metadata
6. Fig. 6. Results of 24-hours blood pressure monitoring of patient M., 55 years old, before correction of therapy

Download (106KB)
Indexing metadata
7. Fig. 7. Control 24-hours blood pressure monitoring of patient M., 55 years old, while taking a combination of azilsartan medoxomil 40 mg and amlodipine 5 mg (Edarbi AM)

Download (113KB)
Indexing metadata
8. Fig. 8. Electrocardiography results of patient M., 66 years old

Download (465KB)
Indexing metadata
9. Fig. 9. Results of 24-hours blood pressure monitoring of patient M., 66 years old, before correction of therapy

Download (111KB)
Indexing metadata
10. Fig. 10. Control 24-hours blood pressure monitoring of patient M., 66 years old, during the intake of a combination of azilsartan medoxomil 40 mg 1 tablet + amlodipine 10 mg 1 tablet (Edarbi AM) for 2 months

Download (87KB)
Indexing metadata

Copyright (c) 2025 Russkiy Vrach Publishing House